APA (7th ed.) Citation

H, Z., W, T., S, S., R, B., AN, T., L, H., . . . M, G. (2026). Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve. Clinical pharmacokinetics, 65(5), 747. https://doi.org/10.1007/s40262-026-01631-7

Chicago Style (17th ed.) Citation

H, Zhang, et al. "Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve." Clinical Pharmacokinetics 65, no. 5 (2026): 747. https://doi.org/10.1007/s40262-026-01631-7.

MLA (9th ed.) Citation

H, Zhang, et al. "Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve." Clinical Pharmacokinetics, vol. 65, no. 5, 2026, p. 747, https://doi.org/10.1007/s40262-026-01631-7.